Fundraising FoxEliem Therapeutics
NASDAQ: CLYMWilmington, US · Founded 2018 · Delaware corporation · 7 known investors
Find your way into Eliem Therapeutics
Sign up to see every warm intro you have to Eliem Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eliem Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
Founders & leadership
EL
Erin LavelleExecutiveErin Lavelle is an executive officer at Eliem Therapeutics with prior roles at ProfoundBio, Neoleukin Therapeutics, Alder Biopharmaceuticals, Amgen, and Merrill Lynch's Healthcare Investment Banking Division, including assignments in Asia; she holds a BA in Economics from Yale University and has expertise in capital raising, M&A, corporate finance, and general management in the life sciences sector.
RA
Robert AzelbyExecutive
JB
James BucherExecutive
LP
Leone PattersonNamed on SEC filing
Board
AR
Adam RosenbergBoard director
LR
AL
ST
Stephen ThomasBoard director
ST
Simon TateBoard director
AB
Aoife BrennanBoard director
JD
Judith DunnBoard director
Investors · 7
Manta Ray Ventureslisted by Manta Ray VenturesLondon
How we know: Manta Ray Ventures's portfolio page · Not right? Tell us
Intermediate Capital GroupreportedLondon · $5M – $50M
How we know: prnewswire.com · Not right? Tell us
LifeArc VenturesreportedLondon
How we know: prnewswire.com · Not right? Tell us
RA CapitalreportedBoston
How we know: the S-1 prospectus · prnewswire.com · Not right? Tell us
Also in the syndicate · 1
Samlyn Capital
Reported raises · per SEC filings
Form D private placements$363.2M disclosed across 7 rounds · 2019–2026
▶$110.1MraisedMay 2026 · 22 investors · BiotechnologyRule 506(b)
▶$110.1MraisedMay 2026 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aoife BrennanExecutive Officer, Director
- Perrin WilsonExecutive Officer
- Stephen ThomasDirector
- Douglas WilliamsDirector
- Susan AltschullerExecutive Officer
- Kimberlee DrapkinDirector
- Alexander (Bo) ComboDirector
- Judith DunnDirector
- Andrew LevinDirector
- Offering amount
- $110.1M
- Amount sold
- $110.1M
- Sales commissions
- $6.3M
- Placement agents
- BTIG, LLC, Raymond James & Associates, Inc., Piper Sandler and Co., Robert W. Baird & Co. Incorporated, H.C. Wainwright & Co., LLC, Leerink Partners LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$41.9MraisedJul 2024 · 6 investors · BiotechnologyRule 506(b)
▶$41.9MraisedJul 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Judith DunnDirector
- Stephen ThomasDirector
- Andrew LevinExecutive Officer, Director
- Adam RosenbergDirector
- Aoife BrennanExecutive Officer, Director
- Liam RatcliffeDirector
- Valerie MorissetExecutive Officer
- Simon TateDirector
- Offering amount
- $41.9M
- Amount sold
- $41.9M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$120MraisedJul 2024 · 8 investors · BiotechnologyRule 506(b)
▶$120MraisedJul 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam RosenbergDirector
- Stephen ThomasDirector
- Liam RatcliffeDirector
- Simon TateDirector
- Andrew LevinExecutive Officer, Director
- Aoife BrennanExecutive Officer, Director
- Judith DunnDirector
- Valerie MorissetExecutive Officer
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedMay 2021 · 9 investors · PharmaceuticalsRule 506(b)
▶$60MraisedMay 2021 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- Erin LavelleExecutive Officer
- Liam RatcliffeDirector
- Judith DunnDirector
- Valerie MorissetExecutive Officer
- Robert AzelbyExecutive Officer, Director
- James BucherExecutive Officer
- Simon TateDirector
- Adam RosenbergDirector
- Leone PattersonDirector
- Offering amount
- $60M
- Amount sold
- $60M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5MraisedNov 2020 · 4 investors · PharmaceuticalsRule 506(b)
▶$5MraisedNov 2020 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Simon TateDirector
- James BucherExecutive Officer
- Adam RosenbergDirector
- Liam RatcliffeDirector
- Andrew LevinExecutive Officer, Director
- Robert AzelbyExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $5M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$10MraisedOct 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$10MraisedOct 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David-Alexandre GrosDirector
- Valerie MorissetExecutive Officer
- Simon TateDirector
- Andrew LevinExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$16.3MraisedOct 2019 · 6 investors · PharmaceuticalsRule 506(b)
▶$16.3MraisedOct 2019 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Simon TateDirector
- Valerie MorissetExecutive Officer
- Andrew LevinExecutive Officer, Director
- David-Alexandre GrosDirector
- Offering amount
- $16.3M
- Amount sold
- $16.3M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$317Mvaluation at IPOAug 2021 · $12.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Eliem Therapeutics do?
- Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
- Who are Eliem Therapeutics's investors?
- Eliem Therapeutics's investors include Manta Ray Ventures, Access Biotechnology, ACORN BIOVENTURES, Intermediate Capital Group, LifeArc Ventures, RA Capital.
- How much funding has Eliem Therapeutics raised?
- Eliem Therapeutics has disclosed $363.2M raised across 7 rounds.
- Where is Eliem Therapeutics headquartered?
- Eliem Therapeutics is headquartered in Wilmington, US.